Anti-CD79a [JCB117]
Invented by Dr Jacqueline Cordell from University of Oxford
Invented at University of Oxford
- Datasheet
- References (18)
- Inventor Info
Info
| Catalogue Number | 151375 |
| Applications | IHC WB |
| Antigen/Gene or Protein Targets | CD79a |
| Synonyms | CD79a Molecule; Membrane-Bound Immunoglobulin-Associated Protein; Surface IgM-Associated Protein; MB-1 Membrane Glycoprotein; Ig-Alpha; IGA; CD79a Antigen; MB1 |
| Reactivity | Human |
| Relevance | The B-cell Antigen receptor constitutes a disulphide linked heterodimer, consisting of CD79a (mb1) and CD79b / B29 polypeptides which are non-covalently associated with membrane bound immunoglobulins on B-cells. CD79a first appears at pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in B-cell lymphomas, in B-cell lines, the majority of acute leukemias of precursor B-cell type and in some myelomas. The CD79a/b heterodimer interacts with at least one tyrosine kinase (Lyn). The induction of tyrosine kinase activity after antigen binding leads to phosphorylation of the CD79a/b dimer, and also of other molecules, thereby initiating intracellular signalling. CD79a is widely used as an adjunct to CD20 as a biomarker for normal and neoplastic B-cells in tissues sections. |
| Host | Mouse |
| Immunogen | Synthetic peptide of 14 amino acids representing residues 202-216 of the human mb-1 cDNA sequence |
| Subclass | IgG1 |
| Myeloma Used | P3/NS1/1-Ag4.1 |
| Recommended Growing Conditions | RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| Notes |
Ultroser G can be used at 1% if the cells are not growing well. Western Blot (WB) 1:100-1:500 Immunohistochemistry (Paraffin) (IHC (P)) 1:50-1:100 Flow Cytometry (FACS) 2 ug/test |
| Research Area | Cancer, Cell Signaling & Signal Transduction, Immunology, Stem Cell Biology |
References: 18 entries
HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens.
Europe PMC ID: 27484914
Arana et al. 2016. J Clin Pathol. :. PMID: 27484914.
Delli et al. 2016. Ann Rheum Dis. :. PMID: 26757748.
Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Europe PMC ID: 26757748
Higashi et al. 2015. Leuk Lymphoma. :1-6. PMID: 25860238.
Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
Europe PMC ID: 25860238
Radaev et al. 2010. Structure. 18(8):934-43. PMID: 20696394.
Structural and functional studies of Igalphabeta and its assembly with the B cell antigen receptor.
Europe PMC ID: 20696394
Boudova et al. 2006. J Cutan Pathol. 33(8):584-9. PMID: 16919035.
Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman.
Europe PMC ID: 16919035
Boudova et al. 2005. Am J Dermatopathol. 27(5):375-86. PMID: 16148405.
Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients.
Europe PMC ID: 16148405
Pilozzi et al. 1998. J Pathol. 186(2):140-3. PMID: 9924428.
Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.
Europe PMC ID: 9924428
Mason et al. 1995. Blood. 86(4):1453-9. PMID: 7632952.
CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.
Europe PMC ID: 7632952
Korkolopoulou et al. 1994. Histopathology. 24(6):511-5. PMID: 7520411.
The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease.
Europe PMC ID: 7520411
Add a reference
References: 18 entries
HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens.
Arana et al. 2016. J Clin Pathol. :. PMID: 27484914.
Delli et al. 2016. Ann Rheum Dis. :. PMID: 26757748.
Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Higashi et al. 2015. Leuk Lymphoma. :1-6. PMID: 25860238.
Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
Radaev et al. 2010. Structure. 18(8):934-43. PMID: 20696394.
Structural and functional studies of Igalphabeta and its assembly with the B cell antigen receptor.
Boudova et al. 2006. J Cutan Pathol. 33(8):584-9. PMID: 16919035.
Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman.
Boudova et al. 2005. Am J Dermatopathol. 27(5):375-86. PMID: 16148405.
Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients.
Pilozzi et al. 1998. J Pathol. 186(2):140-3. PMID: 9924428.
Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.
Mason et al. 1995. Blood. 86(4):1453-9. PMID: 7632952.
CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.
Korkolopoulou et al. 1994. Histopathology. 24(6):511-5. PMID: 7520411.
The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease.
Add a reference
